ArticleIndian journal of endocrinology and metabolism2011
Management of diabetic hypertensives.
Article in Indian journal of endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Intensive vs standard blood pressure control in adults with type 2 diabetes: a systematic review and GRADE-based meta-analysis.Annals of medicine and surgery (2012) · 2026Article
- Prevalence of Prehypertension Among Adults in Baghdad/Iraq.International journal of hypertension · 2026Article
- Pathophysiological mechanisms and benefits of SGLT?2 inhibitors in a patient with cerebral artery aneurysm: A case report.Experimental and therapeutic medicine · 2025Article
- Strategies for Cardiovascular Disease Prevention in Type 1 Diabetes: A Comprehensive Review.Cureus · 2024Review
- Review
- Review
- Interactions between diabetic and hypertensive drugs: a pharmacogenetics approach.Molecular genetics and genomics : MGG · 2023Review
- RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus.International journal of diabetes in developing countries · 2022Review
- Evaluation of Medical Care for Diabetic and Hypertensive Patients in Primary Care in Mexico: Observational Retrospective Study.Journal of diabetes research · 2021Observational
- Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.British journal of pharmacology · 2020Article
- Article
- Blood Glucose Regulation for Post-Operative Patients with Diabetics and Hypertension Continuum: A Cascade Control-Based Approach.Journal of medical systems · 2019Article
- The dirty dozen of diabetes.Indian journal of endocrinology and metabolism · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension occurs twice as commonly in diabetics than in comparable nondiabetics. Patients with both disorders have a markedly higher risk for premature microvascular and macrovascular complications. Aggressive control of blood pressure (BP) reduces both micro- and macrovascular complications. In diabetic hypertensives, angiotensin converting enzyme inhibitors (ACEIs) are the first line in management of hypertension, and can be replaced by angiotensin II receptor blockers (ARBs) if patients are intolerant of them. Recent studies suggest ARBs to be on par with ACEI in reducing both macro- and microvascular risks. Adding both these agents may have a beneficial effect on proteinuria, but no extra macrovascular risk reduction. Thiazides can also be used as first line drugs, but are better used along with ACEI/ARBs. Beta-blockers [especially if the patient has coronary artery disease] and calcium channel blockers are used as second line add-on drugs. Multidrug regimens are commonly needed in diabetic hypertensives. Achieving the target BP of <130/80 is the priority rather than the drug combination used in order to arrest and prevent the progression of macro- and microvascular complications in diabetic hypertensives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.